6,7-dichloro-3,4-dihydrobenzothiopyran-4-carboxylic acid | 76301-89-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 6,7-dichloro-3,4-dihydrobenzothiopyran-4-carboxylic acid
• 英文别名: 6,7-dichloro-thiochroman-4-carboxylic acid；6,7-dichloro-3,4-dihydro-2H-thiochromene-4-carboxylic acid
• CAS: 76301-89-8
• 化学式: C₁₀H₈Cl₂O₂S
• 分子量: 263.144
• InChiKey: UPLSQALLBFGVAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6,7-dichloro-4-cyano-4-trimethylsilyloxy-3,4-dihydro-2H-1-benzothiopyran 、 、 溶剂黄146 以concentrated hydrochloric acid (30 ml.) to form 6,7-dichloro-3,4-dihydro-2H-1-benzothiopyran-4-carboxylic acid的产率得到盐酸
  参考文献：
  名称：

  Halogen substituted benzopyran- and benzothiopyran-4-carboxylic acids

  摘要：

  本发明揭示了新型卤代苯并吡喃-4-羧酸、苯并噻吩-4-羧酸及其衍生物，其作为醛糖还原酶抑制剂和治疗慢性糖尿病并发症的治疗剂。具体揭示的化合物包括6-苯基-8-氯-3,4-二氢-2H-1-苯并吡喃-4-羧酸、6,7-二氯-3,4-二氢苯并噻吩-4-羧酸、6-氯-8-甲基-3,4-二氢-2H-1-苯并吡喃-4-羧酸、6,8-二氯-3,4-二氢-2H-1-苯并吡喃-4-羧酸、6-氟-3,4-二氢-2H-1-苯并吡喃-4-羧酸、6-氯-3,4-二氢-2H-1-苯并吡喃-4-羧酸、6-氯-二氢-2H-萘并[1,2-b]吡喃-4-羧酸、6-氯-3,4-二氢-2H-1-苯并噻吩-4-羧酸和6-氯-3,4-二氢-2H-1-苯并吡喃-4-乙酸。本发明还揭示了含有新型化合物的制药组合物以及使用新型化合物治疗慢性糖尿病并发症的方法。

  公开号：

  US04210663A1

文献信息

• NK1 and NK3 antagonists
  申请人：O'Neill T. Brian

  公开号：US20050256164A1

  公开（公告）日：2005-11-17

  The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.

  这项发明涉及一种具有神经激肽抑制性能的化合物，包括该化合物的药物组合物以及用于神经激肽介导疾病的治疗方法。
• Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same
  申请人：PFIZER INC.

  公开号：EP0011426A1

  公开（公告）日：1980-05-28

  Benzopyran- and benzothiopyran-4 -carboxylic acid aldose reductase inhibitors of the formula: or a pharmaceutically acceptable salt thereof, wherein X is 0, S,S=0 or n is zero or one; R is hydrogen or alkyl of 1 to 4 carbon atoms; R1 is hydrogen, chloro, bromo, fluoro or phenyl; R2 and R3 when taken individually, are each hydrogen, alkyl of 1 to 3 carbon atoms, chloro, bromo or fluoro; and when taken together, R2' R3 and the carbon atoms to which they are connected form a fused benzene ring; with the proviso that at least one of R1, R2 and R3 is chloro, bromo or fluoro. The compounds are useful in the treatment of diabetic- associated complications, such as cataracts, neuropathy or retinopathy, in a diabetic host. Also disclosed are methods for preparing the compounds of the formula (I) and their salts, and pharmaceutical compositions containing them.

  式中的苯并吡喃和苯并噻喃-4-羧酸醛糖还原酶抑制剂： 或其药学上可接受的盐，其中 X 是 0、S、S=0 或 n 为 0 或 1；R 为氢或 1 至 4 个碳原子的烷基；R1 为氢、氯、溴、氟或苯基；R2 和 R3 单独使用时，各自为氢、1 至 3 个碳原子的烷基、氯、溴或氟；R2' R3 和它们连接的碳原子一起使用时，形成融合苯环；但 R1、R2 和 R3 中至少有一个为氯、溴或氟。这些化合物可用于治疗糖尿病宿主的糖尿病相关并发症，如白内障、神经病变或视网膜病变。还公开了制备式（I）化合物及其盐类的方法，以及含有这些化合物的药物组合物。
• PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1748984A1

  公开（公告）日：2007-02-07
• US4210663A
  申请人：——

  公开号：US4210663A

  公开（公告）日：1980-07-01
• [EN] PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS<br/>[FR] DERIVES DE PIPERIDINE EN TANT QU'ANTAGONISTES DE NK1 ET NK3
  申请人：PFIZER PROD INC

  公开号：WO2005110987A1

  公开（公告）日：2005-11-24

  The invention relates to compounds according to formula I exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising, same and a method of treatment for neurokinin-mediated conditions. Formula (I) or a pharmaceutically acceptable salt or solvate thereof wherein: m,=0 or 1; n =0 or 1; s=0 or 1; L is -O- or -N(R4 )-; R1 and R2 are each independently H, aryl, heteroaryl, -(C1-C6)atkylheterocyloalkyl, -(C1-C6)alkylheterocycloalkyl, -(C1-C6)alkylheteroaryl, -(C1-C6)alkyl-O-aryl, -(C1- C6)alkylaryl, and -CH2 N(R4)(R5), wherein each of said heterocyloalkyl, -(C1-C6)alkylheterocycloalkyl, -(C1-C6)alkylheteroaryl, -(C1-C6)alkyl-0-aryl, aryl, -(C1-C6)alkylaryl, heteroaryl, and -CH2N(R4)(R5), is optionally substituted with 1-3 moieties independently selected from X', Y' or Z'; R3 is H, CF3, OH, or-(C1-C6)alkyl; R4, and R5, are each independently selected from H, -(C1-C6)alkyl, or -(C1-C6)(C=0)R7; R7 is (C1-C6)alkyl, OH, -N(R4)(R), or -OR4; R8 and R9 are each independently (C1-C6)alkyl; X, Y, X', Y' and Z' are each independently selected from H, -(C1-C6)alkyl, -(C1-C6)alkyl-NR 4R5, CF3, OH, -O-(C1-C6)alkyl, -(C1-C6)alkyl-C(=0)R7, aryl, heteroaryl, cycloalkyl, -N02, -(C1-C6)alkylaryl, -0-aryl, halogen, CN, -CH3N(R4)(R5), -C(=O)R7, -C(=O)R7, -R6C(=0)R7 or -R6C(=O)NR4R5; and R6 is a bond, -CH2-, -0-, or -NR4­.